Abstracts tagged "Psoriatic arthritis and spondylarthritis"

Abstract Number: 547 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical and Imaging Characteristics of Axial Psoriatic Arthritis and Axial Spondyloarthritis
Neha Garg¹, Abhijeet Danve², Kiana Vakil-Gilani³ and Atul A. Deodhar⁴, ¹Arthritis & Rheumatic Diseases, Oregon Health and Sciences University, Portland, OR, ²Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³OHSU, Portland, OR, ⁴Oregon Health and Science University, Portland, OR
Background/Purpose Few studies have compared the clinical and imaging (x-ray and MRI) characteristics between axial psoriatic arthritis (axPsA) and axial spondyloarthritis patients without psoriasis (axSpA).…
Abstract Number: 545 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
Philip J. Mease¹, Roy Fleischmann², Jurgen Wollenhaupt³, Atul A. Deodhar⁴, Dafna D. Gladman⁵, Bengt Hoepken⁶, Luke Peterson⁷ and Désirée M. van der Heijde⁸, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁴Oregon Health and Sciences University, Portland, OR, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶UCB Pharma, Monheim, Germany, ⁷Biostatistics US Group, UCB Pharma, Raleigh-Durham, NC, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 48 weeks (wks) in psoriatic arthritis (PsA) patients (pts), including…
Abstract Number: 2306 • 2013 ACR/ARHP Annual Meeting
Comparative Study Of Patients With Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis and Axial Spondyloarthritis Without Psoriasis
Abhijeet Danve¹, Neha Garg² and Atul A. Deodhar³, ¹Rheumatology, Oregon Health and Science University, Portland, OR, ²Internal Medicine, Division of arthritis and rheumatic diseases, Oregon Health and Sciences University, Portland, OR, ³Oregon Health and Science University, Portland, OR
Background/Purpose: Axial involvement in Psoriatic Arthritis (PsA) is reported to be between 40 -70%. Both, axial and peripheral arthritis in patients with PsA can cause…
Abstract Number: 524 • 2013 ACR/ARHP Annual Meeting
Expansion Of DC-STAMP⁺ IL-17⁺ Cells In Bone Marrow From Psoriasis and Psoriatic Arthritis Patients
Yahui Grace Chiu¹, Edward M. Schwarz², Jamie Biear¹, Debbie Campbell³, Jennifer Hossler¹, Jennifer H. Anolik⁴, R. John Looney¹ and Christopher T. Ritchlin¹, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, Univerity of Rochester, Rochester, NY, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Focal erosions in inflammatory arthritis are mediated by bone marrow (BM) derived osteoclasts (OC) that enter the joint as OC precursors (OCP) from peripheral…
Abstract Number: 313 • 2013 ACR/ARHP Annual Meeting
The DC-STAMP⁺IL17A⁺ Cell Subset Is Elevated In Psoriatic Arthritis (PsA) Patients and Declines Following Anti-TNFi Therapy
Yahui Grace Chiu¹, Edward M. Schwarz², Hua He³, Francisco A. Tausk⁴, Sharon Moorehead⁵, Michelle Smith⁵ and Christopher T. Ritchlin⁵, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Biostatistics and Computational Biology, University of Rochester, Rochester, NY, ⁴Dermatology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop psoriatic arthritis (PsA), a potentially destructive joint disease, within 10 years of Ps onset. Although early diagnosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].